Videos
Downloads
Press Release – 6 Nov 18 – Abzena announces 20m$ investment
Download the 6th November 2018 release.
DownloadEvents
References
Building a biologics capabilities network
This article explains how Abzena is building a biologics capabilities network through a slew of acquisitions. GEN May[...] Read more
News
Abzena Appoints Louise Duffy as Senior Vice President and Head of Scientific Project Leadership
Abzena, the leading Partner Research Organization (PRO) for outsourced solutions integrating gene to GMP services for[...] Read more
Information on Abzena’s Response to COVID-19
This page will remain up to date on Abzena’s response to COVID-19 Last updated 16:15 GMT 8th June 2020 Abzena[...] Read more
Information on Abzena’s Response to COVID-19
This page will remain up to date on Abzena’s response to COVID-19 Last updated 15:00 GMT 17th March 2020 The[...] Read more
Abzena Names Kimball Hall as Chief Operating Officer
Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive[...] Read more
Abzena expands leadership team with Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer
San Diego, USA , 21 June 2019 – Abzena, the leading global biologics and ADC target partner research organization,[...] Read more
Abzena expands management team: appoints Campbell Bunce to the role of Chief Scientific Officer and Bo Adair as Senior Vice President Process and Operations
Cambridge, UK and San Diego, USA, 28 March 2019 – Abzena, the leading global biologics target to GMP partner research[...] Read more
ABZENA ANNOUNCES APPOINTMENT OF ELAINE SAPINOSO AS GLOBAL HEAD OF QUALITY
Addition of experienced leadership in GMP Quality as Abzena increases capacity in biologics and complex small molecule[...] Read more
Abzena announces 20m$ investment into expansion of integrated biotherapeutics offering (Biologics Drug Substance and ADC) and makes key executive appointment
Significant increase in capacity to 2000 L scale in new GMP facility, addition of extra cell line development capacity[...] Read more
Ken Cunningham, Chairman of Abzena Limited, announced today the appointment of Jonathan Goldman, MD as Chief Executive Officer (CEO) following completion of the Acquisition by Welsh, Carson, Anderson & Stowe (WCAS)
Dr. Goldman will focus his efforts on the growth of Abzena as the leading provider of outsourced and integrated services[...] Read more
Faron Pharmaceuticals Ltd announces that it has filed a Clinical Trial Application (CTA)
Faron Pharmaceuticals Ltd today announced that it has filed a Clinical Trial Application (CTA) for Clevegen®, an ABZENA[...] Read more